biontech
German vaccine manufacturer BioNTech saw profits fall dramatically in 2023, as revenue from Covid-19 vaccines dropped sharply and the company invested in research on new cancer drugs. BioNTech, based in the western German city of Mainz, reported net profits in 2023 of €930.3 million ($1.01 billion) on Wednesday. That was a major drop from the €9.4 billion in profits the company reported in 2022. BioNTech plans to launch its first cancer drug on the market in 2026, chief executive Uğur Şahin announced on Wednesday during a presentation of the company's financial results. He said that the compan...
DPA
German vaccine manufacturer BioNTech saw profits fall dramatically in 2023, as revenue from Covid-19 vaccines dropped sharply and the company invested in research on new cancer drugs. BioNTech, based in the western German city of Mainz, reported net profits in 2023 of €930.3 million ($1.01 billion) on Wednesday. That was a major drop from the €9.4 billion in profits the company reported in 2022. BioNTech plans to launch its first cancer drug on the market in 2026, chief executive Uğur Şahin announced on Wednesday during a presentation of the company's financial results. He said that the compan...
DPA International
German vaccine manufacturer BioNTech saw profits fall dramatically in 2023, as revenue from Covid-19 vaccines dropped sharply and the company invested in research on new cancer drugs. BioNTech, based in the western German city of Mainz, reported net profits in 2023 of €930.3 million ($1.01 billion) on Wednesday. That was a major drop from the €9.4 billion in profits the company reported in 2022. BioNTech plans to launch its first cancer drug on the market in 2026, chief executive Uğur Şahin announced on Wednesday during a presentation of the company's financial results. He said that the compan...
DPA Breaking News
Der Impfstoffhersteller Biontech will im Jahr 2026 sein erstes Krebsmedikament auf den Markt bringen. Bis 2030 streben die Mainzer Zulassungen in zehn Indikationen an. Das kündigte Unternehmenschef Ugur Sahin bei der Vorstellung der Geschäftszahlen für das Gesamtjahr 2023 an. In der Onkologie seien mehrere Partnerschaften geschlossen und zahlreiche klinische Fortschritte erzielt worden. Im am 31. Dezember zu Ende gegangenen Geschäftsjahr 2023 stand am Ende ein Nettogewinn von 930,3 Millionen Euro zu Buche. Das war vor allem aufgrund des schrumpfenden Geschäfts mit Covid-19-Impfstoff deutlich w...
DPA (German)
Eine Klage gegen den Impfstoffhersteller Biontech wegen vermeintlicher Impfschäden hat das Landgericht im pfälzischen Frankenthal abgewiesen. Die Klägerin hatte von dem Mainzer Pharmakonzern unter anderem Schmerzensgeld in Höhe von mindestens 200.000 Euro gefordert, wie das Gericht mitteilte. Sie habe nach ihrer zweiten Corona-Impfung eine beidseitige Lungenarterienembolie erlitten, gab die Frau aus Rheinland-Pfalz nach Angaben des Gerichts an. Dabei handelt es sich um eine Verstopfung von Blutgefäßen in der Lunge. Außerdem leide sie seit der Impfung an einer Immunschwäche. Dass die Impfung di...
DPA (German)
BioNTech had a strong quarter despite slowing COVID sales.A robust pipeline makes it a takeover target for larger pharma companies.A share repurchase program should help support price action in 2023.5 stocks we like better than BioNTechBioNTech (NASDAQ:BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE:PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held ...
ValueWalk
Washington (AFP) - Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world. The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease. "Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement....
AFP
Pfizer and BioNTech will start a clinical trial for an Omicron-specific vaccine. The study will include three cohorts of healthy adult participants ranging from ages 18 to 55. The first group will include those who had two doses of the Pfizer vaccine at least 90 to 180 days ahead of the study. They will receive either one or two doses of the Omicron vaccine. The second group will be made of participants who have had three doses of the Pfizer vaccine, also at least 90-180 days prior. This group will be given one dose of the Omicron-specific vaccine. Finally, the third group will include partici...
uPolitics.com
Vaccine manufacturers Pfizer and BioNTech have announced that two doses of their Covid-19 vaccine provide significant protection against the rapidly spreading omicron variant and that a supplemental booster shot was found to “neutralize” the mutated pathogen, based on blood tests that they conducted from individuals who had received second and third injections. “Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers,” the pharmaceutica...
uPolitics.com
The Food and Drug Administration approved COVID-19 vaccine booster shots for people with weakened immune systems, according to CNBC. With this move, the organization intends to protect the most vulnerable population from the delta variant, now prevalent in the country. Q2 2021 hedge fund letters, conferences and more Covid Booster AuthorizedActing FDA Commissioner Dr. Janet Woodcock said in a statement: “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19.” The measure will mean that organ transplant recipients, and H...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら